A Study of Oxytocin in Children and Adolescents With Autistic Disorder

This study has been completed.
Sponsor:
Collaborator:
Autism Speaks
Information provided by (Responsible Party):
Linmarie Sikich, MD, University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier:
NCT01308749
First received: February 28, 2011
Last updated: September 10, 2013
Last verified: September 2013

February 28, 2011
September 10, 2013
March 2011
April 2013   (final data collection date for primary outcome measure)
Tolerability [ Time Frame: Over 16 weeks double blind and open treatment phase ] [ Designated as safety issue: Yes ]
This study will help to determine tolerability of intranasal oxytocin treatment in children with autism by measuring the ability of at least 80% of the sample to tolerate twice daily intranasal administration of oxytocin.
  • Feasibility [ Time Frame: During total study duration, 76 weeks. ] [ Designated as safety issue: No ]
    The overarching goal of this pilot study is to determine the feasibility of conducting a larger study of intranasal oxytocin in children with autism.
  • Tolerability of Oxytocin Nasal Spray [ Time Frame: During the 16 week treatment phase ] [ Designated as safety issue: Yes ]
    This study will help to determine tolerability of intranasal oxytocin treatment in children with autism by measuring the ability of at least 80% of the sample to tolerate twice daily intranasal administration of oxytocin. Evidence of parent and participant, when developmentally appropriate, satisfaction will also help to determine this.
  • Biomarkers [ Time Frame: During 3 time points in the study: (1) Screening or Baseline, (2) Week 8, and (3) Week 16 ] [ Designated as safety issue: No ]
    Blood samples will be collected to obtain proof of concept data regarding the potential utility of OTX mRNA expression, OTXR methylation and OTXR mRNA expression as biomarkers for social disabilities in autism or oxytocin treatment response.
  • Acceptability of Oxytocin Nasal Spray [ Time Frame: During the 16 week treatment phase ] [ Designated as safety issue: Yes ]
    The study will to determine acceptability by examining the incidence and severity of systematically elicited adverse events and abnormal labs, vitals signs, and electrocardiographic abnormalities. Evidence of parent and participant, when developmentally appropriate, satisfaction will also help to determine this.
Complete list of historical versions of study NCT01308749 on ClinicalTrials.gov Archive Site
  • Biomarkers [ Time Frame: During 3 time points in the study: (1) Screening or Baseline, (2) Week 8, and (3) Week 16 ] [ Designated as safety issue: No ]
    Blood samples will be collected to obtain proof of concept data regarding the potential utility of OTX mRNA expression, OTXR methylation and OTXR mRNA expression as biomarkers for social disabilities in autism or oxytocin treatment response.
  • Adverse effects of Oxytocin Nasal Spray [ Time Frame: During the 16 week, blinded and open treatment phases ] [ Designated as safety issue: Yes ]
    The study will examine the incidence and severity of systematically elicited adverse events and abnormal labs, vitals signs, and electrocardiographic abnormalities.
  • Satisfaction [ Time Frame: 16 weeks, 8 wks blinded & 8 wks ope ] [ Designated as safety issue: No ]
    Caregivers (and participants when developmentally appropriate) will complete ratings of satisfaction with the treatment at the end of each treatment phase
  • Social reciprocity [ Time Frame: 8 weeks, blinded treatment ] [ Designated as safety issue: No ]
    The SRS will be used to assess social interest and skills
  • ADOS Severity Score [ Time Frame: Baseline to 16 Weeks ] [ Designated as safety issue: No ]

    The Autism Diagnostic Observation Schedule (ADOS) is a semi-structured assessment used to assess and diagnose individuals suspected of having autism of varying ages, developmental levels, and language skills (from no speech to verbally fluent). The ADOS includes four modules, each requiring just 35-40 minutes to administer. The individual being evaluated is given just one module, depending on his or her expressive language level and chronological age. The rater will observe social and communication behaviors during various activities in the appropriate module.

    We will graphically examine the relationship between baseline levels of the biomarker measures and the within-subject change for severity at each of the major time points during oxytocin treatment and placebo treatment.

  • ABC-Social Withdrawal [ Time Frame: Baseline to 16 Weeks ] [ Designated as safety issue: No ]

    The Aberrant Behavior Checklist (ABC) focuses on problem behaviors in five sub-domains: irritability, attention, repetitive behaviors, unusual speech, and social withdrawal.

    We will graphically examine the relationship between the ABC-Social Withdrawal sub-domain and baseline levels of the biomarker measures at each of the major time points during oxytocin treatment and placebo treatment.

  • Pervasive Developmental Disorder Behavior Inventory (PDD-BI) [ Time Frame: Baseline to 16 Weeks ] [ Designated as safety issue: No ]

    The PDD-BI examines both adaptive and maladaptive behaviors related to autism. It has normative scores for children between 2-11 years. For children 12 years and older, the norms (11 years, 11 months) will be used.

    We will graphically examine the relationship between the PDD-BI outcome measure and the baseline levels of the biomarker measures at each of the major time points during oxytocin treatment and placebo treatment.

Not Provided
Not Provided
Not Provided
 
A Study of Oxytocin in Children and Adolescents With Autistic Disorder
A Pilot Study of Oxytocin in Children and Adolescents With Autistic Disorder

The investigators propose to conduct this pilot study to evaluate oxytocin as a supplemental treatment for improving social difficulties in individuals with autism.

The proposed pilot study is an essential first step toward rigorously evaluating oxytocin treatment of individuals with autism. The biologic actions of oxytocin on social cognition and prosocial behaviors and the clinical, genetic and epigenetic evidence for involvement of the oxytocin system in the pathophysiology of some cases of autism strongly suggest that supplemental oxytocin therapy could significantly improve the social disabilities involved in autism. Many people feel that these social difficulties are the most characteristic and central feature of autism. Overall, this study aims to determine the tolerability, accessibility, and feasibility of an oxytocin pilot study.

This study will consent up to 30 subjects in order to randomize up to 25 subjects into a 2-month (8 weeks) randomized double-blind, placebo-controlled initial treatment period, a subsequent 2-month (8 weeks) period in which all participants receive oxytocin, and up to three post-treatment visits that occur at week 28 (±2 weeks),an interim visit anytime between week 16 and week 76 only for those patients who plan to start oxytocin on their own outside of study treatment and who will experience a lag time between week 16 (end of open label treatment) and when outside oxytocin treatment will begin, and some time before week 76. The investigators hope that this study will help to inform future study designs in determining whether a short term or long term treatment trial is necessary to observe significant effects. This will also help to develop systematic preliminary safety measures.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Autism
  • Drug: Oxytocin

    Subjects will use the Syntocinon® Nasal Spray (oxytocin) twice daily for 8 weeks if they are randomized to that arm in the Randomized Phase. All subjects will use the Syntocinon® Nasal Spray twice daily for 8 weeks in the Open Label Phase.

    Subjects ages 3-10 years old will be titrated up to a maximum dose of 24IU. Subjects ages 11-17 years old will be titrated up to a maximum dose of 32IU.

    Other Name: Syntocinon® Nasal Spray
  • Drug: Placebo
    Placebo Nasal Spray
    Other Name: Placebo
  • Placebo Comparator: Placebo
    Intervention: Drug: placebo
    Intervention: Drug: Placebo
  • Active Comparator: Oxytocin
    Intervention: Drug: Syntocinon® Nasal Spray
    Intervention: Drug: Oxytocin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
April 2013
April 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Between 3 and 17 years old, inclusive.
  • Have a clinical diagnosis of autistic disorder confirmed according to DSM-IV criteria by using the Autism Diagnostic Interview - Revised (ADI-R) and/or the Autism Diagnostic Observation Scale (ADOS, Lord et al., 1989).

Exclusion Criteria:

  • Changes in allied health therapies, behavioral or educational interventions within the past 2 months of the baseline visit other than those associated with school holidays.
  • Changes in psychotropic and alternative medication doses in the last 30 days of the baseline visit.
  • Subjects with a medical condition that might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own well-being. This includes, but is not limited to, Rett Syndrome, impairment of renal function, evidence or history of malignancy or any significant hematological, endocrine, cardiovascular (including any rhythm disorder and uncontrolled hypertension), respiratory, hepatic, or gastrointestinal disease.
  • Marked sensory impairment such as deafness or blindness that would interfere with conduct of the study.
  • Pregnancy/Nursing because of the unknown effects of oxytocin to unborn babies and/or nursing infants. All females of child-bearing potential will be administered a urine or serum pregnancy test at screening and at any point during the study at physician discretion. Refusal to undergo a pregnancy test will result in exclusion from the study. The investigators will share results of pregnancy test with the subject's legal guardian.
  • Refusal to practice contraception if sexually active because the effects of exposure to high concentrations of oxytocin on sperm or newly conceived embryos are unknown. Sexually active men and women should not take part in this study if they and their partners are not both using an effective birth control method (for example, women use birth control pills, an intrauterine device [IUD] or a diaphragm and men use condoms).
  • Inability of caretakers to speak English.
  • Absence of a consistent caretaker to report on symptoms.
  • Subjects who, in the Investigator's opinion, might not be suitable for the study.
Both
3 Years to 17 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01308749
11-0493
No
Linmarie Sikich, MD, University of North Carolina, Chapel Hill
University of North Carolina, Chapel Hill
Autism Speaks
Principal Investigator: Linmarie Sikich, M.D. University of North Carolina, Chapel Hill
University of North Carolina, Chapel Hill
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP